Novartis loses Glivec patents case in India


The apex Indian court rejected Swiss based pharmaceutical company Novartis AG’s plea for retaining patent of its cancer drug Glivec. The development has the potential for better prospects for Indian pharmaceutical firms over well placed foreign brands.

A logo is pictured on a building of Swiss drug maker Novartis before its annual general meeting in Pratteln

According to analysts, the Supreme Court has set a legal precedent with this decision where it refuses to support patents on existing drugs sold in India. The decision is not a great sign for foreign firms in the middle of intellectual property disputes in India. This includes companies such as Pfizer Inc and Roche Holding AG.

Source: Reuters, WSJ

Published by Bhavesh Kumar

A multi-talented media professional with diverse experience spanning across journalism (digital and broadcast), management consultancy and documentary filmmaking. Worked for the leading newspaper (the Times of India) and news broadcaster (NDTV India) on their web portal, feature stories, shooting, scripting, programming and editing broadcast news. A creative mindset focused on executing new-age strategic communication initiatives with all its corresponding elements (clear and coherently written key messages, social media marketing and multimedia content) to ensure effective target audience impressions. Also, worked on several primary and secondary market research projects (Market Feasibility Study) for business expansion into new markets.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

This site uses Akismet to reduce spam. Learn how your comment data is processed.

%d bloggers like this: